Peptide Knowledge Base · Metabolic
Orforglipron: what it is, what the evidence says, and its real status
An investigational non-peptide, small-molecule oral GLP-1 agonist, 'GLP-1 in a daily pill.'
Short version: not a peptide, a small molecule taken as a daily pill that activates the GLP-1 receptor. The convenience story of the category. Investigational; not approved, not available.
Can you actually get it?
Plain-English verdict: Watch / education.
Regulatory status: Investigational (Phase 3) · Not yet approved.
Not available to prescribe. Orforglipron is an investigational non-peptide oral GLP-1 agonist (Eli Lilly) in Phase-3 trials. Not FDA-approved, not compoundable, we cover it as category context, not an offer.
How does Orforglipron work?
A non-peptide small molecule that activates the GLP-1 receptor, enabling once-daily oral dosing without injection.
What it does — and what it does not do
What it does: Studied for weight and glycemic control as an oral, injection-free GLP-1 option.
What it does not do: It is not a peptide, not approved, and not available; we tag it adjacent and capture the query.
How honest is the evidence?
Evidence grade B — Phase-2 data; Phase-3 ongoing, re-verify. Read our grading methodology for what each grade means.
What we still don't know: Long-term efficacy versus injectable agonists and full safety are still being established.
WADA status: Not prohibited.
How it is taken
What the literature reports: oral, once daily. Educational only, no dose figures.
Who should not take it
Investigational, safety not fully characterized; clinician-gated.
Sources
Orforglipron Phase-2 (NEJM 2023) · Phase-3 program (ongoing, re-verify)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.